- Trials with a EudraCT protocol (44,380)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
44,380 result(s) found.
Displaying page 1,234 of 2,219.
| EudraCT Number: 2013-004620-10 | Sponsor Protocol Number: 719-13 | Start Date*: 2014-12-22 |
| Sponsor Name:Johan Hellgren | ||
| Full Title: A double blind, placebo controlled randomized study of nasal steroid spray treatment on the quality of life and objective sleep parameters in children with sleep disorder breathing. | ||
| Medical condition: Sleep disordered breathing due to enlarged tonsils and/or adenoid | ||
| Disease: | ||
| Population Age: Children, Under 18 | Gender: Male, Female | |
| Trial protocol: SE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-005628-16 | Sponsor Protocol Number: Uni-Koeln-1473 | Start Date*: 2012-08-06 |
| Sponsor Name:University of Cologne | ||
| Full Title: FTO-genotype dependent weight reduction under treatment with bromocriptin in obese patients | ||
| Medical condition: Obesity with BMI ≥ 30kg/m² | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2005-004740-31 | Sponsor Protocol Number: | Start Date*: 2005-12-21 | |||||||||||
| Sponsor Name:University of Copenhagen | |||||||||||||
| Full Title: Efficacy of B-cell depletion with rituximab on oral, ocular and general disease manifestations in patients with primary Sjögren disease | |||||||||||||
| Medical condition: Previously treated patients with primary Sjögrens disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Female | ||||||||||||
| Trial protocol: DK (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-022687-12 | Sponsor Protocol Number: STREAM | Start Date*: 2011-03-17 | |||||||||||
| Sponsor Name:Universitätsklinikum Essen | |||||||||||||
| Full Title: A Randomized Discontinuation, Blinded, Placebo-Controlled, Phase II Study of Sorafenib in Patients with Chemonaïve Metastatic Uveal Melanoma (Sorafenib Treatment of Metastatic Uveal Melanoma) | |||||||||||||
| Medical condition: choroid melanoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-000147-98 | Sponsor Protocol Number: 20060159 | Start Date*: 2007-08-14 | |||||||||||
| Sponsor Name:Amgen Inc. | |||||||||||||
| Full Title: A Randomized, Double Blinded, Multi-Center Study 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metas... | |||||||||||||
| Medical condition: A Randomized, Double Blinded, Multi-Center Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination with AMG 386 or Placebo in Subjects with Metas... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) BE (Completed) AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-003592-39 | Sponsor Protocol Number: EFC10145 | Start Date*: 2008-04-17 |
| Sponsor Name:sanofi-aventis recherche et développement | ||
| Full Title: A multinational, randomized, double-blind placebo controlled study of AVE8062 (25 mg/m²) administered every 3 weeks in patients with advanced-stage soft tissue sarcoma, treated with cisplatin (75 m... | ||
| Medical condition: advanced-stage soft tissue sarcoma treated with cisplatin after failure of anthracycline and ifosfamide chemotherapies. | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: FR (Completed) BE (Completed) ES (Completed) GB (Completed) HU (Completed) IT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2007-005837-13 | Sponsor Protocol Number: COU-AA-301 | Start Date*: 2008-06-10 | |||||||||||
| Sponsor Name:Cougar Biotechnology, Inc | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Abiraterone Acetate (CB7630) Plus Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Doceta... | |||||||||||||
| Medical condition: Metastatic Castration-Resistant Prostate Cancer in Patients who have Failed Docetaxel-Based Chemotherapy. | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: IE (Completed) GB (Completed) FR (Completed) DE (Completed) BE (Completed) HU (Completed) AT (Completed) ES (Completed) NL (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-006195-11 | Sponsor Protocol Number: BC1-06 | Start Date*: 2008-03-26 | |||||||||||
| Sponsor Name:Algeta ASA | |||||||||||||
| Full Title: A double-blind, randomised, multiple dose, Phase III, multicentre study of Alpharadin in the treatment of patients with symptomatic hormone refractory prostate cancer with skeletal metastases. | |||||||||||||
| Medical condition: Hormone refractory prostate cancer with skeletal metastases | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male | ||||||||||||
| Trial protocol: SE (Completed) FR (Completed) GB (Completed) BE (Completed) SK (Completed) ES (Completed) CZ (Completed) NL (Completed) IT (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-004953-27 | Sponsor Protocol Number: CV185-057 | Start Date*: 2008-07-29 | ||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM (Apixaban after the initial Management of PuLmonary embolIsm an... | ||||||||||||||||||
| Medical condition: Venous Thromboembolism (VTE) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) FR (Completed) PT (Completed) GB (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) ES (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-006212-38 | Sponsor Protocol Number: 20080580 | Start Date*: 2009-07-06 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: Phase 2, Open-label Single-Arm, Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects with Advanced or Inoperable Hepatocellular Carcinoma. | |||||||||||||
| Medical condition: advanced or inoperable hepatocellular carcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012083-14 | Sponsor Protocol Number: EPC2008-02 | Start Date*: 2009-06-17 | |||||||||||
| Sponsor Name:MEDA Pharma GmbH & Co. KG | |||||||||||||
| Full Title: An Open-Label, Multicenter Study of the Effects of Remission Maintenance Therapy with Ceplene® (Histamine Dihydrochloride), Given in Conjunction with Low-Dose Interleukin-2 (IL-2, Proleukin®), on I... | |||||||||||||
| Medical condition: Acute Myeloid Leukemia in First Complete Remission (CR1) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: SE (Completed) BE (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) FR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-011739-11 | Sponsor Protocol Number: H3E-EW-S128 | Start Date*: 2009-08-04 | ||||||||||||||||
| Sponsor Name:Eli Lilly and Company Limited | ||||||||||||||||||
| Full Title: Phase 2 Study of Pemetrexed and Cisplatin as Induction, Followed by Pemetrexed and Cisplatin with Concurrent Thoracic Radiotherapy, in Patients with Unresectable Locally-Advanced Stage III, Non-Squ... | ||||||||||||||||||
| Medical condition: Non-small Cell Lung Cancer | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) ES (Completed) IT (Completed) DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-004439-39 | Sponsor Protocol Number: 0881X1-4535-WW | Start Date*: 2009-12-22 | |||||||||||
| Sponsor Name:Wyeth Research Division of Wyeth Pharmaceuticals Inc. A Pfizer Company,Philadelphia,PA-19101,USA | |||||||||||||
| Full Title: Randomized Open-label Study Comparing 2 Different Strategies For Management of Subjects With Plaque Psoriasis Who Have Responded to Etanercept Treatment | |||||||||||||
| Medical condition: Plaque psoriasis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) HU (Completed) FR (Completed) GR (Completed) DE (Completed) ES (Completed) PT (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-003003-31 | Sponsor Protocol Number: EORTC 26082 – 22081 | Start Date*: 2009-12-01 | |||||||||||
| Sponsor Name:EORTC Headquarters | |||||||||||||
| Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra... | |||||||||||||
| Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2007-005439-27 | Sponsor Protocol Number: SP902 | Start Date*: 2009-02-16 | ||||||||||||||||
| Sponsor Name:UCB BIOSCIENCES, Inc. | ||||||||||||||||||
| Full Title: A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures | ||||||||||||||||||
| Medical condition: Partial-onset seizures (with or without secondary generalization) | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Completed) IE (Completed) ES (Completed) AT (Completed) DK (Completed) PT (Not Authorised) IT (Completed) FR (Completed) DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-007167-16 | Sponsor Protocol Number: CA163-196 | Start Date*: 2009-09-29 | ||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
| Full Title: A Phase III Open Label, Randomized, 2 Arm Study of Ixabepilone Administered Every 21 Days Versus Paclitaxel or Doxorubicin Administered Every 21 Days in Women with Advanced Endometrial Cancer Who H... | ||||||||||||||||||
| Medical condition: Advanced, recurrent or metastatic endometrial carcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||
| Trial protocol: GB (Completed) BE (Completed) IT (Prematurely Ended) ES (Temporarily Halted) FR (Completed) SE (Completed) GR (Completed) DK (Completed) HU (Completed) FI (Completed) CZ (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-016758-42 | Sponsor Protocol Number: GS-US-236-0103 | Start Date*: 2010-06-28 | |||||||||||
| Sponsor Name:Gilead Sciences Incorporated | |||||||||||||
| Full Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitab... | |||||||||||||
| Medical condition: Human Immunodeficiency Virus (HIV-1) Infections | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) FR (Completed) PT (Completed) BE (Completed) NL (Completed) AT (Completed) ES (Prematurely Ended) DK (Completed) IT (Completed) SE (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-018329-20 | Sponsor Protocol Number: LN-LAQ-201 | Start Date*: 2010-05-07 | |||||||||||
| Sponsor Name:Teva Pharmaceutical Industries Ltd. | |||||||||||||
| Full Title: A Phase IIa, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Clinical Effect of Laquinimod in Active Lupus Nephritis Patients, in Combinati... | |||||||||||||
| Medical condition: Active Lupus Nephritis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-018411-15 | Sponsor Protocol Number: 28431754DIA3010 | Start Date*: 2010-07-16 | |||||||||||
| Sponsor Name:Janssen-Cilag International NV | |||||||||||||
| Full Title: A Randomized, Double-Blind, Placebo-controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Canagliflozin Compared With Placebo in the Treatment of Older... | |||||||||||||
| Medical condition: Type 2 Diabetes Mellitus | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: FR (Completed) SE (Completed) PL (Completed) ES (Completed) GB (Completed) GR (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-022111-19 | Sponsor Protocol Number: FDC114615 | Start Date*: 2010-11-22 | |||||||||||
| Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
| Full Title: Study FDC114615: Comparative efficacy of DuodartTM plus lifestyle advice versus watchful waiting plus lifestyle advice with step-up therapy to tamsulosin in the management of treatment naïve men wi... | |||||||||||||
| Medical condition: Benign prostatic hyperplasia | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male | ||||||||||||
| Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) FR (Completed) GR (Completed) IT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.